How Valid and Responsive Are Generic Health Status Measures, such as EQ-5D and SF-36, in Schizophrenia? A Systematic Review

Objectives Generic health status measures such as the short form health survey (SF-36) and EuroQol-5D (EQ-5D) are increasingly being used to inform health policy. They are claimed to be applicable across disease areas and have started to be used within mental health research. This review aims to assess the construct validity and responsiveness of four generic health status measures in schizophrenia, including the preference-based SF-6D and EQ-5D. Method A systematic review of the literature was undertaken. Ten databases were searched from inception to August 2009 and reference lists scrutinized to identify relevant studies. Studies were appraised and data extracted. A narrative synthesis was performed of the evidence on construct validity including known groups validity (detecting a difference in health-related quality of life (HRQL) scores between two different groups such as samples from the general population and people with schizophrenia), convergent validity (strength of association between generic HRQL and other measures (e.g., symptom or functional), and responsiveness. Responsiveness was considered by: 1) differences in generic HRQL measure scores in responders/non-responders and 2) correlation between changes on generic HRQL measures and changes in specific measures obtained from patients and clinicians. Results Thirty-three studies were identified that provided data on the validity and/or responsiveness of the instruments. Most of the evidence concerns the SF-36 and EQ-5D, and for these instruments there was evidence for known group validity. The evidence for convergent validity and responsiveness was mixed, with studies presenting contradictory results. Conclusion Although the evidence base is limited in a number of important respects, including problems with the measures used to develop constructs in the validation studies, it is sufficient to raise doubts about the use of generic measures of health like the EQ-5D and SF-36 in patients with schizophrenia.

[1]  A. Loundou,et al.  Assessing health-related quality of life in patients suffering from schizophrenia: a comparison of instruments , 2005, European Psychiatry.

[2]  Peter B. Jones,et al.  Measuring the benefits of treatment for psychosis: validity and responsiveness of the EQ–5D , 2009, British Journal of Psychiatry.

[3]  Jacqueline L Johnson,et al.  Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode , 2005, Schizophrenia Research.

[4]  G. Andrews,et al.  Prevalence and severity of mental health-related disability and relationship to diagnosis. , 2002, Psychiatric services.

[5]  Jacob Cohen.  Statistical Power Analysis for the Behavioral Sciences , 1969, The SAGE Encyclopedia of Research Design.

[6]  R. Chan,et al.  Impact of Untreated Psychosis on Quality of Life in Patients with First-episode Schizophrenia , 2005, Quality of Life Research.

[7]  L. Mantovani,et al.  PMH39 RELATIONSHIP BETWEEN CLINICAL OUTCOMES AND PATIENTS' REPORTED OUTCOMES IN SCHIZOPHRENIA: THE CONTRIBUTION OF THE EQ-5D , 2008 .

[8]  D. Naber,et al.  The relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidone. , 2006, The Journal of clinical psychiatry.

[9]  M. Angermeyer,et al.  Validity of the EQ-5D in assessing and valuing health status in patients with schizophrenic, schizotypal or delusional disorders , 2007, European Psychiatry.

[10]  T. Patterson,et al.  Functioning and well-being of middle-aged and older patients with schizophrenia: measurement with the 36-item short-form (SF-36) health survey. , 2003, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[11]  J. Brazier.  Is the EQ–5D fit for purpose in mental health? , 2010, British Journal of Psychiatry.

[12]  X. Badia,et al.  Psychometric validation of a generic health-related quality of life measure (EQ-5D) in a sample of schizophrenic patients , 2004, Current medical research and opinion.

[13]  X. Badia,et al.  Antipsychotic treatment and changes in health related quality of life in patients with schizophrenia using EQ-5D , 2000, Schizophrenia Research.

[14]  P. Bech,et al.  Quality of life assessment in schizophrenia: Applicability of the Lehman Quality of Life Questionnaire (TL-30) , 2007, Nordic journal of psychiatry.

[15]  E. Dunayevich,et al.  Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder. , 2007, The Journal of clinical psychiatry.

[16]  Application of a disease-specific mapping function to estimate utility gains with effective treatment of schizophrenia , 2005, Health and quality of life outcomes.

[17]  C. Lançon,et al.  Development and validation of a patient-based health-related quality of life questionnaire in schizophrenia: the S-QoL , 2003, Schizophrenia Research.

[18]  Kiyoshi Kurokawa,et al.  Estimating a preference-based index from the Japanese SF-36. , 2009, Journal of clinical epidemiology.

[19]  T. Shibre,et al.  Health related quality of life (SF-36) survey in Butajira, rural Ethiopia: normative data and evaluation of reliability and validity. , 2004, Ethiopian medical journal.

[20]  Carol A. Trujillo,et al.  The MOS 36-Item Short Form Health Survey: reliability, validity, and preliminary findings in schizophrenic outpatients. , 1998, Medical care.

[21]  D. Streiner,et al.  Health Measurement Scales: A practical guide to thier development and use , 1989 .

[22]  John E. Ware,et al.  SF-36 physical and mental health summary scales : a user's manual , 1994 .

[23]  D. Revicki,et al.  Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: Quality of life and clinical outcomes of a randomized clinical trial , 1999, Quality of Life Research.

[24]  P. Bebbington,et al.  Side‐effects of antipsychotic medication and health‐related quality of life in schizophrenia , 2009, Acta psychiatrica Scandinavica. Supplementum.

[25]  H. Nasrallah,et al.  Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone. , 2004, The Journal of clinical psychiatry.

[26]  M. Angermeyer,et al.  Utility Assessment in Patients with Mental Disorders , 2012, PharmacoEconomics.

[27]  J. Ware,et al.  A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. , 1996, Medical care.

[28]  R. Obenchain,et al.  Reliability, validity, and application of the medical outcomes study 36-item short-form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol. , 1999, Medical care.

[29]  M. Aapro,et al.  A systematic review of the use and validation of health-related quality of life instruments in older cancer patients. , 2009, European journal of cancer.

[30]  Stephen J. Walters,et al.  Quality of Life Outcomes in Clinical Trials and Health-Care Evaluation: A Practical Guide to Analysis and Interpretation , 2009 .

[31]  J. Brazier,et al.  A checklist for judging preference-based measures of health related quality of life: learning from psychometrics. , 1999, Health economics.

[32]  A. Schene,et al.  Quality of life in schizophrenia measured by the MOS SF‐36 and the Lancashire Quality of Life Profile: a comparison , 2002, Acta psychiatrica Scandinavica.

[33]  Jill Carlton,et al.  The impact of age-related macular degeneration on health status utility values. , 2005, Investigative ophthalmology & visual science.

[34]  M. Ruggeri,et al.  A comparison of SF-6D and EQ-5D utility scores in a study of patients with schizophrenia. , 2009, The journal of mental health policy and economics.

[35]  M. Barkham,et al.  Using Rasch analysis to form plausible health states amenable to valuation: the development of CORE-6D from a measure of common mental health problems (CORE-OM) , 2011, Quality of Life Research.

[36]  T. Sheldon,et al.  Outcome measures and needs assessment tools for schizophrenia and related disorders. , 2003, The Cochrane database of systematic reviews.

[37]  M. Abrahamowicz,et al.  Are indirect utility measures reliable and responsive in rheumatoid arthritis patients? , 2005, Quality of Life Research.

[38]  G. Wilkinson,et al.  Self-report quality of life measure for people with schizophrenia: the SQLS. , 2000, The British journal of psychiatry : the journal of mental science.

[39]  H. Kraemer,et al.  Physical and mental health-related quality of life among older people with schizophrenia , 2009, Schizophrenia Research.

[40]  H. Möller,et al.  Reliability and validity of Quality of Life assessed by the Short-Form 36 and the Modular System for Quality of Life in patients with schizophrenia and patients with depression , 2003, Psychiatry Research.

[41]  J. Pyne,et al.  Comparing the Sensitivity of Generic Effectiveness Measures With Symptom Improvement in Persons With Schizophrenia , 2003, Medical care.

[42]  John Bankart,et al.  Comparing utility scores before and after hearing-aid provision , 2004, Applied health economics and health policy.

[43]  T. Shibre,et al.  Short-term symptomatic and functional outcomes of schizophrenia in Butajira, Ethiopia , 2005, Schizophrenia Research.

[44]  J. Brazier,et al.  Preference-based condition-specific measures of health: what happens to cross programme comparability? , 2010, Health economics.

[45]  J. Jenner,et al.  Changes in quality of life in chronic psychiatric patients: A comparison between EuroQol (EQ-5D) and WHOQoL , 2005, Quality of Life Research.

[46]  M. Konieczyńska.  Quality of life in schizophrenia: Impact of psychopathology, patients' gender and antipsychotic treatment , 2001, International journal of psychiatry in clinical practice.

[47]  J. Brazier,et al.  The estimation of a preference-based measure of health from the SF-36. , 2002, Journal of health economics.

[48]  J. Brazier,et al.  The Estimation of a Preference-Based Measure of Health From the SF-12 , 2004, Medical care.

[49]  Keith Tolley,et al.  What are health utilities , 2009 .